Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8084973 | 0.84 | EPHX2 (0.35) | — | |
| SCHEMBL4259456 | 0.82 | BRD4 (0.47) | POLBCA12CA9LMNAHTT | |
| SCHEMBL5578429 | 0.81 | CNR2 (0.35) | LMNASMN1; SMN2 | |
| SCHEMBL8085302 | 0.81 | ALDH1A1 (0.37) | HIF1A | |
| SCHEMBL9475113 | 0.81 | ESPL1 (0.37) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL8084219 | 0.77 | KDM4E (0.36) | ATMHTTSMN1; SMN2 | |
| SCHEMBL8077246 | 0.76 | HSD11B1 (0.34) | — | |
| SCHEMBL8084230 | 0.76 | HRH4 (0.30) | — | |
| SCHEMBL9796819 | 0.76 | HRH4 (0.34) | POLBLMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL8085076 | 0.76 | NPSR1 (0.34) | HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| CN-1077888-C | Benzopyrans and pharmaceutical compositions containing them | NOVARTIS AG (CH) | 2002-01-16 | — | — | CN | disclosed |
| US-5905156-A | POTASSIUM CHANNEL ACTIVATORS AND BRONCHODILATORS | NOVARTIS AG (CH) | 1999-05-18 | — | — | US | disclosed |
| CN-1185153-A | Benzopyrans and pharmaceutical composition contg. same | CIBA GEIGY AG (CH) | 1998-06-17 | — | — | CN | disclosed |
| EP-0828733-A1 | BENZOPYRANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Novartis AG (CH) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037490-A1 | BENZOPYRANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NOVARTIS AG (CH) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ATM 3694/4885L3MBTL1 2793/4885POLB 3729/4885 |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | ATM 2406/4885L3MBTL1 1290/4885POLB 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.